# Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients

> **NCT01099436** · PHASE3 · COMPLETED · sponsor: **Borstkanker Onderzoek Groep** · enrollment: 250 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** docetaxel
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** zoledronic acid
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT01099436
- **Lead sponsor:** Borstkanker Onderzoek Groep
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-04
- **Final completion:** 2013-09
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2020-01-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01099436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01099436, "Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01099436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*